Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder
NCT06349083Phase 2Recruiting
- Sponsor
- NYU Langone Health
- Start
- Sep 2026
- Primary completion
- May 2030
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in alcohol use disorder (AUD) comparing Oral high-dose of psilocybin with Placebo control (2 arms). Primary endpoints: Percent change in the alcohol cue-induced Blood-oxygen-level dependent (BOLD) signal in the lateral prefrontal cortex (PFC) at Day 2, Percent change in the alcohol cue-induced BOLD signal change in the caudate at Day 2 and 21 more. Started Sep 2026; status: recruiting.
02
Drugs
psilocybin
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT06349083.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06349083.